145 related articles for article (PubMed ID: 19355827)
1. Retrobulbar 99mTc-diethylenetriamine-pentaacetic-acid uptake may predict the effectiveness of immunosuppressive therapy in Graves' ophthalmopathy.
Ujhelyi B; Erdei A; Galuska L; Varga J; Szabados L; Balazs E; Bodor M; Cseke B; Karanyi Z; Leovey A; Mezosi E; Burman KD; Berta A; Nagy EV
Thyroid; 2009 Apr; 19(4):375-80. PubMed ID: 19355827
[TBL] [Abstract][Full Text] [Related]
2. The impact of 99mTc-DTPA orbital SPECT in patient selection for external radiation therapy in Graves' ophthalmopathy.
Szabados L; Nagy EV; Ujhelyi B; Urbancsek H; Varga J; Nagy E; Galuska L
Nucl Med Commun; 2013 Feb; 34(2):108-12. PubMed ID: 23196678
[TBL] [Abstract][Full Text] [Related]
3. Orbital scintigraphy with [111In-diethylenetriamine pentaacetic acid-D-phe1]-octreotide predicts the clinical response to corticosteroid therapy in patients with Graves' ophthalmopathy.
Colao A; Lastoria S; Ferone D; Pivonello R; Macchia PE; Vassallo P; Bonavolonta G; Muto P; Lombardi G; Fenzi G
J Clin Endocrinol Metab; 1998 Nov; 83(11):3790-4. PubMed ID: 9814448
[TBL] [Abstract][Full Text] [Related]
4. Imaging of disease activity in Graves' orbitopathy with different methods: comparison of (99m)Tc-DTPA and (99m)Tc-depreotide single photon emission tomography, magnetic resonance imaging and clinical activity scores.
Galuska L; Leovey A; Szucs-Farkas Z; Szabados L; Garai I; Berta A; Balazs E; Varga J; Nagy EV
Nucl Med Commun; 2005 May; 26(5):407-14. PubMed ID: 15838422
[TBL] [Abstract][Full Text] [Related]
5. 99mTc-DTPA SPECT/CT provided guide on triamcinolone therapy in Graves' ophthalmopathy patients.
Liu D; Xu X; Wang S; Jiang C; Li X; Tan J; Deng Z
Int Ophthalmol; 2020 Mar; 40(3):553-561. PubMed ID: 31792849
[TBL] [Abstract][Full Text] [Related]
6. New Multi-Parameters Combination of Technetium-99m-Diethylene-Triamine-Pentaacetate Orbital Single-Photon Emission Computed Tomography/Computed Tomography for the Evaluation of Graves' Orbitopathy Activity.
Sun L; Peng R; Sun R
Semin Ophthalmol; 2024 Jul; 39(5):387-393. PubMed ID: 38411131
[TBL] [Abstract][Full Text] [Related]
7. SPECT using 99mTc-DTPA for the assessment of disease activity in Graves' ophthalmopathy: a comparison with the results from MRI.
Galuska L; Leovey A; Szucs-Farkas Z; Garai I; Szabo J; Varga J; Nagy EV
Nucl Med Commun; 2002 Dec; 23(12):1211-6. PubMed ID: 12464787
[TBL] [Abstract][Full Text] [Related]
8. Technetium-99m-anti-tumour necrosis factor alpha scintigraphy as promising predictor of response to corticotherapy in chronic active Graves' ophthalmopathy.
de Lacerda AM; de Souza SAL; Gutfilen B; Barbosa da Fonseca LM; Lobo Lopes FPP; Tonomura E; Vaisman M; Teixeira PFDS
Clin Physiol Funct Imaging; 2019 Mar; 39(2):135-142. PubMed ID: 30325581
[TBL] [Abstract][Full Text] [Related]
9. Orbital gallium-67 scintigraphy in Graves' ophthalmopathy.
Konuk O; Atasever T; Unal M; Ayvaz G; Yetkin I; Cakir N; Arslan M; Hasanreisoglu B
Thyroid; 2002 Jul; 12(7):603-8. PubMed ID: 12193305
[TBL] [Abstract][Full Text] [Related]
10. (99m)Tc-HYNIC-TOC scintigraphy in evaluation of active Graves' ophthalmopathy (GO).
Sun H; Jiang XF; Wang S; Chen HY; Sun J; Li PY; Ning G; Zhao YJ
Endocrine; 2007 Jun; 31(3):305-10. PubMed ID: 17906380
[TBL] [Abstract][Full Text] [Related]
11. Rapid response to and long-term effectiveness of anti-CD20 antibody in conventional therapy resistant Graves' orbitopathy: A five-year follow-up study.
Erdei A; Paragh G; Kovacs P; Karanyi Z; Berenyi E; Galuska L; Lenkey A; Szabados L; Gyory F; Ujhelyi B; Berta A; Boda J; Berta E; Bodor M; Gazdag A; Nagy EV
Autoimmunity; 2014 Dec; 47(8):548-55. PubMed ID: 25039242
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of
Szumowski P; Abdelrazek S; Żukowski Ł; Mojsak M; Sykała M; Siewko K; Maliszewska K; Popławska-Kita A; Myśliwiec J
BMC Endocr Disord; 2019 Jan; 19(1):10. PubMed ID: 30658624
[TBL] [Abstract][Full Text] [Related]
13. A pilot study evaluating 99mTc-anti-TNF-alpha scintigraphy in graves' ophtalmopathy patients with different clinical activity score.
Rebelo Pinto Edos S; Lopes FP; de Souza SA; da Fonseca LM; Vaisman M; Gutfilen B; dos Santos Teixeira Pde F
Horm Metab Res; 2013 Sep; 45(10):765-8. PubMed ID: 23918686
[TBL] [Abstract][Full Text] [Related]
14. Early Stage Graves' Disease is Uniformly Accompanied by Orbital Immune Activity even in Patients who Fail to Develop Orbithopathy during Follow-up.
Berta E; Bodor M; Galuska L; Paragh G; Erdei A; Gazdag A; Ujhelyi B; Berényi E; Katkó M; Gazsó A; Nagy EV
Exp Clin Endocrinol Diabetes; 2018 Nov; 126(10):628-631. PubMed ID: 29388175
[TBL] [Abstract][Full Text] [Related]
15. Orbital gallium-67 scintigraphy in Graves' ophthalmopathy: a disease activity parameter that predicts the therapeutic response to immunosuppressive treatment.
Konuk O; Atasever T; Unal M; Ayvaz G; Yetkin I; Cakir N; Arslan M; Hasanreisoglu B
Thyroid; 2005 Apr; 15(4):358-63. PubMed ID: 15876160
[TBL] [Abstract][Full Text] [Related]
16. 99mTc(V)-DMSA SPECT for the assessment of disease activity in Graves' ophthalmopathy.
Reyhan M; Toygar O; Sukan A; Seydaoglu G; Bakiner OS; Aydin M; Yapar AF; Aktas A
Nucl Med Commun; 2007 Oct; 28(10):775-81. PubMed ID: 17728607
[TBL] [Abstract][Full Text] [Related]
17. The role of 99mTc-DTPA retrobulbar SPECT in staging and follow-up of Graves' orbitopathy.
Galuska L; Barna SK; Varga J; Garai I; Nagy EV
Nucl Med Rev Cent East Eur; 2018; 21(1):54-58. PubMed ID: 29319139
[TBL] [Abstract][Full Text] [Related]
18. [Evaluation of inflammatory activity in thyroid associated ophthalmopathy by SPECT/CT with 99mTc-DTPA].
Liu D; Xu X; Wen D; Tan J; Jiang C
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Apr; 43(4):457-460. PubMed ID: 29774886
[TBL] [Abstract][Full Text] [Related]
19. [Nontarget area and threshold selection in 99mTc-DTPA orbital SPECT/CT imaging inthyroid associated ophthalmopathy].
Jiang C; Li X; Dend H; Liu J; Huang J; Liu D; Xu X
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Aug; 43(8):869-874. PubMed ID: 30197315
[TBL] [Abstract][Full Text] [Related]
20. Octreotide-scintigraphy is a disease-activity parameter in Graves' ophthalmopathy.
Gerding MN; van der Zant FM; van Royen EA; Koornneef L; Krenning EP; Wiersinga WM; Prummel MF
Clin Endocrinol (Oxf); 1999 Mar; 50(3):373-9. PubMed ID: 10435064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
